Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects

NCT03859869 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.

NCT NCT03859869
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03859869 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects
Lead sponsor
AbbVie
Phase
Phase 4
Overall status
Terminated
Start date
February 25, 2020
Completion date
March 23, 2022
Enrollment
1 (actual)
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

exocrine pancreatic insufficiency (epi)